Moderna (MRNA) Stock Plunges Double Digits Amid Heavy Insider Sales and Bearish Analyst Outlook

Key Takeaways

Table of Contents

Shares of Moderna plummeted 10.7% on July 10, 2026, shedding $8.17 to settle at $68.39
Company executives offloaded $6.2 million in shares over the last three months without any insider purchases
First-quarter earnings per share hit -$3.40, falling short of the -$3.02 forecast, while revenue reached $389M, surpassing the $236.37M estimate
The consensus analyst recommendation stands at “Reduce” with an average price target of $38.27
QRG Capital Management established a fresh stake, acquiring 13,666 shares valued at approximately $694,000

Shares of Moderna experienced a significant downturn on July 10, 2026, plunging 10.7% — an $8.17 decline — to finish trading at $68.39. This steep drop reflects mounting concerns surrounding the biotechnology company.

Moderna, Inc., MRNA

Trading commenced that session at $76.56. The biotech firm’s 52-week trading range spans from $22.28 to $85.60, positioning the current valuation in the upper portion of this spectrum — yet the latest pullback indicates growing headwinds at these elevated levels.

The company’s latest quarterly report, unveiled on May 1, provided little support for investors. Moderna reported an earnings loss of $3.40 per share, falling short of the anticipated -$3.02 figure. Markets typically penalize such misses, and this instance proved no exception.

On the top-line front, results appeared more favorable. The pharmaceutical developer generated $389 million in quarterly revenue, significantly exceeding the $236.37 million Wall Street projection. This represents a substantial 260.2% year-over-year increase.

However, strong revenue growth offers limited relief when bottom-line performance remains deeply negative. The company continues to struggle with a net margin of negative 143.55% alongside a return on equity of negative 26.64%.

Executive Stock Sales Intensify Concerns

Corporate insiders have been actively reducing their holdings. Throughout the previous three months, company executives disposed of $6.2 million in shares — with zero purchases recorded during this period.

Board member Noubar Afeyan divested 9,263 shares on May 21 at an average execution price of $46.84, reducing his stake by 70.24%. Company President Stephen Hoge unloaded 53,336 shares on June 15 at $51.37 each, representing approximately $2.74 million in total value.

While these transactions occurred through pre-established 10b5-1 trading programs designed in advance, the substantial selling activity typically raises red flags among market participants.

Company insiders maintain a combined 10.80% ownership stake. Institutional investment firms control 75.33% of outstanding shares.

Analyst Community Maintains Bearish Posture

Wall Street’s perspective on Moderna remains decidedly pessimistic. Among the 18 equity research analysts tracking the stock, just two maintain Buy recommendations, eleven suggest Hold positions, and five advise Sell ratings. The weighted average recommendation calculates to “Reduce.”

The mean price target among analysts stands at $38.27 — representing substantial downside from current trading levels.

Morgan Stanley recently adjusted its price objective upward from $33 to $39 while maintaining an “equal weight” stance. Goldman Sachs lifted its target from $43 to $49 with a “neutral” rating. Bank of America increased its forecast from $34 to $38 but retained an “underperform” designation.

Weiss Ratings confirmed a “sell (d-)” recommendation on June 12.

Regarding institutional activity, QRG Capital Management initiated a new holding during the first quarter, purchasing 13,666 shares with an approximate value of $694,000. Several other smaller investment firms also established positions, though the dollar amounts remained relatively minimal.

Moderna’s GF Score registers at 58 out of a possible 100 points. The Financial Strength component scores 7/10, Growth capability rates 7/10, while Profitability achieves only 3/10.

The 50-day moving average currently sits at $55.75. The 200-day moving average rests at $49.53. Collectively, Wall Street analysts project Moderna will record full-year earnings of -$6.51 per share.

✨ Limited Time Offer